FDA moves a diabetes trial's retinopathy data into Zepbound's obesity label

The Food and Drug Administration approved a labeling supplement for Zepbound on 26 August, and the two-page approval letter behind it is more interesting than a routine prescribing-information update usually is [s1]. It moves the results of a cardiovascular outcomes trial run entirely in people with type 2 diabetes into the label of a drug approved for obesity and sleep apnoea — and, in the process, changes who the label's diabetic retinopathy warning is addressed to.

What was approved

The supplement is a prior-approval sNDA that Eli Lilly dated 24 October 2025 and the agency received on 27 October 2025 [s1]. It provides for updates to the prescribing information adding information from I8F-MC-GPGN, the completed cardiovascular outcomes trial known as SURPASS-CVOT, which compared tirzepatide with dulaglutide in adults with type 2 diabetes and established cardiovascular disease [s1].

Two specific label changes are named in the letter. The first is a change to the Warnings and Precautions subsection on diabetic retinopathy complications, which the letter titles "Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy" and attributes to SURPASS-CVOT [s1]. The second is a revision to Patient Counseling Information to bring it into line with the Dosage and Administration section [s1]. The agency also made one minor editorial revision of its own, to the Dosage Forms and Strengths entry in the Highlights [s1].

The heading is the part worth pausing on. In the structured product label in effect as of 22 April 2026, the corresponding warning was headed "Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus," and its Highlights summary read that Zepbound "has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema," and that clinicians should "monitor patients with a history of diabetic retinopathy for progression" [s3]. The new heading reorganises the warning around retinopathy history rather than around a diabetes diagnosis.

That distinction matters for this particular drug because of what Zepbound is approved to treat. Its indications are weight reduction and long-term maintenance in adults with obesity, or with overweight plus at least one weight-related comorbidity, and moderate-to-severe obstructive sleep apnoea in adults with obesity [s3]. Type 2 diabetes is not among them. A warning keyed to "patients with type 2 diabetes" is, on an obesity label, a warning about a population the label does not formally address; a warning keyed to retinopathy history is not.

What SURPASS-CVOT actually showed

SURPASS-CVOT was an active-comparator, double-blind non-inferiority trial in patients with type 2 diabetes and atherosclerotic cardiovascular disease, randomised 1:1 to weekly subcutaneous tirzepatide up to 15 mg or dulaglutide 1.5 mg [s2]. A total of 13,299 patients were randomised and 134 were subsequently excluded for not meeting inclusion criteria, leaving 6,586 patients on tirzepatide and 6,579 on dulaglutide in the modified intention-to-treat population [s2]. Mean age was 64.1 years (SD 8.8), 29.0% were women, mean body-mass index was 32.6 (SD 5.5), mean glycated haemoglobin was 8.4% (SD 0.9), and mean diabetes duration was 14.7 years (SD 8.8) [s2].

The primary composite of cardiovascular death, myocardial infarction or stroke occurred in 801 patients (12.2%) on tirzepatide and 862 (13.1%) on dulaglutide — a hazard ratio of 0.92 with a 95.3% confidence interval of 0.83 to 1.01, meeting the pre-specified non-inferiority margin of 1.05 (P = 0.003) but not superiority (P = 0.09) [s2]. Adverse events appeared similar between groups, with more gastrointestinal events on tirzepatide [s2]. The trial was funded by Eli Lilly and registered as NCT04255433 [s2].

What is not established

The published trial report's abstract does not break out diabetic retinopathy outcomes, and the FDA letter does not reproduce the new warning text [s1][s2]. So the public record as of the approval date establishes that the retinopathy warning was revised on the basis of SURPASS-CVOT, and that the revision came with a change of heading — but not what the revised paragraph says, whether it reports a numerical imbalance, or in which direction. Readers should treat any account of the substance of the new warning as unverified until the revised prescribing information is posted; the letter requires the sponsor to submit the content of labeling in structured product label format within 14 days of the approval date [s1].

Two further details in the letter are worth recording because they bound what this action was. FDA determined the supplement was exempt from the Pediatric Research Equity Act assessment requirement, because it involved no new active ingredient, indication, dosage form, dosing regimen or route of administration — which is a formal way of saying nothing about who the drug is for changed [s1]. And because Zepbound is a combination product under 21 CFR 3.2(e), the sponsor remains subject to combination-product postmarketing safety reporting [s1].

The letter was signed by the acting associate director of therapeutic review in FDA's Division of Diabetes, Lipid Disorders, and Obesity on 26 August 2026 [s1].

What to watch

The concrete thing to watch is the arrival of the new structured product label in FDA's public repositories, which the letter's 14-day clock makes due in early September [s1]. That will show what the retinopathy paragraph now says and whether the change is a narrowing, a broadening, or a restatement. The broader question the supplement raises — how safety data generated in a diabetes population should be carried across to labels for the same molecule marketed for obesity — is not settled by one supplement, and the letter does not attempt to settle it.

This article describes a regulatory action and the trial behind it. It is not advice about any medicine, and nothing here should be used to start, stop or change treatment.

Sources

• NDA 217806/S-041 supplement approval letter, Zepbound (tirzepatide) injection, US Food and Drug Administration, 26 August 2026
• Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes, New England Journal of Medicine, 1 December 2025
• ZEPBOUND (tirzepatide) injection prescribing information, structured product label, US Food and Drug Administration, label version effective 22 April 2026